Digestive Health Newsletter

IBD and Your Diet

Ellen J. Scherl, MD

Volume 7, 
January 01, 2007

by Ellen J. Scherl, MD

Ellen Scherl Ellen J. Scherl, MD, is Director at the Jill Roberts Center for Inflammatory Bowel Disease, Jill Roberts Associate Professor for Inflammatory Bowel Disease, and Associate Professor of Medicine, Division of Gastroenterology and Hepatology, Weill Medical College of Cornell University, specializing in the medical treatment of inflammatory bowel disease (IBD). She is a principal investigator and participates in clinical trials involving treatments for IBD and has contributed numerous scholarly articles, reviews, and commentaries to the scientific literature of IBD. Dr. Scherl is a member and has served in a leadership capacity of numerous professional societies related to gastroenterology and IBD. She is certified in Internal Medicine and Gastroenterology by the American Board of Internal Medicine. Dr. Scherl was the recipient of the Crohn's and Colitis Foundation's Woman of Distinction Award in 1996.

Table of Contents

Introduction

Inflammatory Bowel Disease (IBD) is an umbrella term for two chronic gastrointestinal diseases: ulcerative colitis (UC) and Crohn's disease (CD). Because IBD affects the digestive tract it is very easy to associate food with the diseases and be concerned that your eating habits caused your IBD. Your disease was not caused by your diet, nor can your diet cure your disease. However, what you eat can affect your symptoms.

While no single special diet or eating plan works for everyone with IBD, you can develop a plan that may help you control your symptoms. You may want to start by reading about how IBD affects digestion. Or, you can skip to the sections that will help you pinpoint the foods that cause your symptoms to flare up or get the vitamins and minerals you need. Keep in mind that IBD can change over time, and you may need to revise your plan accordingly.

How Does IBD Affect Digestion?

When you think about how your body digests food, you probably picture your stomach. In reality, the majority of digestion actually happens in your small intestine, where food travels after it leaves your stomach. That's where digestive juices and churning help to break down what you eat. It's also where nutrients are absorbed into your bloodstream for distribution to the rest of your body. Anything left unabsorbed passes into your large intestine, where water is reabsorbed into your body. The remaining solid food residue leaves your body as a bowel movement.

When you have ulcerative colitis, your small intestine is usually healthy, but your large intestine is inflamed, which makes it difficult to reabsorb water properly and results in diarrhea. When you have Crohn's disease, usually your small intestine is inflamed although your entire digestive tract may become involved, making it less able to digest and absorb nutrients in the foods you eat. These unabsorbed nutrients pass along to your large intestine, where they interfere with water reabsorption, potentially causing both malnutrition and diarrhea.

Back to Top

What Can You Do to Decrease Discomfort and Malnutrition?

Avoid foods that trigger flare-ups.

Many patients report that the following foods and beverages tend to cause problems:

Back to Top

Get the Vitamins and Minerals you need

You may sometimes feel like you are walking a tightrope between avoiding the foods that worsen your symptoms and eating enough food to stay well-nourished. IBD, especially Crohn's disease, can make you prone to malnutrition for several reasons:

To compensate for any of the challenges listed above, your physician may recommend that you supplement the foods you eat with a general multivitamin and/or specific vitamins, minerals, and other essential nutrients. The following list reviews some of the supplements that you may need. Before taking any supplement, be sure to check with your physician.

Back to Top

Get Enough Calories

You may not always feel like eating, but it's important to be sure to get the calories your body needs to stay as healthy as possible. There are simple ways to increase calories without adding a lot of additional food to your diet. For example, add a hard-boiled egg to vegetables and sandwiches; add instant breakfast mix to your milk; eat presweetened cereal; and choose higher calorie fruite juices (cranberry, grape, pineapple, or apricot).

Back to Top

Eat small meals

Eating smaller meals at more frequent intervals may help reduce abdominal pain. For example, instead of three meals per day, try eating smaller meals every three to four hours.

Back to Top

Drink plenty of liquids

Chronic diarrhea increases your risk of dehydration, so focus on getting enough fluids each day, especially in warm weather. Each day, try drinking one-half ounce for every pound you weigh. That means if you weigh 130 pounds, you should try to drink 65 ounces (about 8 cups) per day. Water is the best choice. Make sure you sip instead of gulp, to cut down on discomfort caused by increased air in your digestive track.

Back to Top

Proceed with caution

You may have read about some new approaches to nutritional therapy for IBD. Most are in their infancy and haven't been rigorously studied, so it's important to first discuss them with your physician and then proceed with caution. The National Center for Complementary and Alternative Medicine has developed a Web site (http://nccam.nih.gov) to help you learn more about nontraditional therapies.

Back to Top

Understand the role of nutritional support.

If you become significantly malnourished, there are several different types of nutrition support available. Commercially available, nonprescription formulations, like Ensure and Sustacal can be used to increase the caloric and nutrient content of your diet. These ready-made drinks provide complete nutrition and are easily absorbed in the small intestine.

If you find ready-made drinks difficult to digest or unpalatable, your physician may prescribe an elemental diet, which is even more readily absorbed. Elemental diets can be delivered through a nasogastric tube (through the nose to the stomach) or through a gastronomy tube (directly into the stomach through a surgical opening in the abdominal wall). This is called enteral nutrition. Both types of tubes are typically used during sleep and removed in the morning; however gastronomy tubes can also be used intermittently during the day.

Sometimes severe relapses of IBD require interventions to bypass the digestive tract while ensuring that patients receive the nutrition they need. Should this happen to you, to give your intestines a complete rest, your physician may prescribe a therapy called total parenteral nutrition (TPN), which means that a solution of nutrients is delivered through a catheter or needle placed in a vein in your upper arm or chest. Patients typically start TPN treatment in the hospital. Once stabilized, they can then continue receiving TPN at home. TPN may result in more complications than enteral nutrition. For example, a small number of patients develop liver damage, blood-borne bacterial infections, or clotting within the major vein. It is also significantly more expensive than other types of nutritional support and requires a higher level of training to use.

Back to Top

Summary

Remember, your diet did not cause and cannot cure your disease, but what you eat can have a significant impact on reducing your IBD symptoms, promoting healing, and helping you feel in charge. Avoiding the foods that cause flare-ups and getting adequate calories and nutrients can sometimes feel like a challenge, but there is a healthcare team to help you along the way. Work with your physician and a registered dietitian to develop the best plan for you.

CCFAThis information has been reviewed and approved by CCFA's National Scientific Advisory Committee.


  1. Steiner-Grossman, P, Banks, PA, Present, DH, Eds. The New People Not Patients. New York: Crohns and Colitis Foundation of America;1992:29,117.
  2. Langmead, L, Rampton, DS. Review article: complementary and alternative therapies for inflammatory bowel disease. Aliment Pharmacol Ther. 2006;23:341-349.

Back to Top

Important Safety Information about AZASAN

WARNING: Chronic immunosuppression with this purine antimetabolite increases risk of neoplasia in humans. Physicians using this drug should be very familiar with this risk as well as with the mutagenic potential to both men and women and with possible hematologic toxicities. See WARNINGS section in complete Prescribing Information.

AZASAN® (azathioprine tablets) 75/100 mg is indicated as an adjunct for the prevention of rejection in renal homotransplantations, and also for the management of active rheumatoid arthritis to reduce signs and symptoms.The most commonly reported side effects associated with AZASAN therapy are leukopenia and/or thrombocytopenia, secondary infections, neoplasia, nausea, vomiting, diarrhea, fever, myalgias, skin rashes, and hepatotoxicity. AZASAN therapy should be given cautiously when used concomitantly with allopurinol, ACE inhibitors, and other agents affecting myelopoiesis. AZASAN is contraindicated in pregnant and lactating women and in patients who have shown hypersensitivity to this product.

Consult with your physician to see if this product is right for you.

Complete Prescribing Information for AZASAN, including BOXED WARNINGpdf

Important Safety Information about METOZOLV® ODT

WARNING: TARDIVE DYSKINESIA

See full prescribing information for complete boxed warning.

Treatment with metoclopramide can cause tardive dyskinesia, a serious movement disorder that is often irreversible. The risk of developing tardive dyskinesia increases with the duration of treatment and the total cumulative dose.

Metoclopramide therapy should be discontinued in patients who develop signs or symptoms of tardive dyskinesia. There is no known treatment for tardive dyskinesia. In some patients, symptoms may lessen or resolve after metoclopramide treatment is stopped.

Treatment with metoclopramide for longer than 12 weeks should be avoided in all but rare cases where therapeutic benefit is thought to outweigh the risk of developing tardive dyskinesia.

METOZOLV® ODT (metoclopramide HCl) is indicated as short-term (4 to 12 weeks) therapy for adults with symptomatic, documented gastroesophageal reflux disease (GERD) who fail to respond to conventional therapy and for the relief of symptoms associated with acute and recurrent diabetic gastroparesis (diabetic gastric stasis) in adults. Therapy should not exceed 12 weeks in duration. Take on an empty stomach up to four times daily, at least 30 minutes before eating and at bedtime.

METOZOLV ODT is contraindicated in patients with intestinal obstruction, hemorrhage, or perforation; pheochromocytoma; known sensitivity or intolerance to metoclopramide; epilepsy; or are receiving concomitant medications with extrapyramidal reactions.

Extrapyramidal symptoms (EPS), manifested primarily as acute dystonic reactions, occur in approximately 1 in 500 patients treated with the usual adult dosages of 30 to 40 mg/day of metoclopramide. These usually are seen during the first 24 to 48 hours of treatment with metoclopramide, occur more frequently in pediatric patients and adult patients less than 30 years of age and are even more frequent at higher doses.

Drug-induced Parkinsonism can occur during metoclopramide therapy, more commonly within the first 6 months after beginning treatment, but also after longer periods. Patients with a history of Parkinson’s disease should be given metoclopramide cautiously, if at all, since such patients can experience exacerbation of Parkinsonian symptoms when taking metoclopramide.

There have been rare reports of an uncommon but potentially fatal symptom complex sometimes referred to as Neuroleptic Malignant Syndrome (NMS) associated with metoclopramide. Clinical manifestations of NMS include hyperthermia, muscle rigidity, altered consciousness, and evidence of autonomic instability. The management of NMS should include immediate discontinuation of metoclopramide and other drugs not essential to concurrent therapy.

Depression associated with metoclopramide use has occurred in patients with and without a history of depression. For those patients with a prior history of depression, metoclopramide should only be given if the expected benefits outweigh the potential risks.

In one study in hypertensive patients, intravenously administered metoclopramide was shown to release catecholamines; hence, caution should be exercised when metoclopramide is used in patients with hypertension. Any rapid rise in blood pressure associated with METOZOLV ODT use should result in immediate cessation of metoclopramide use in those patients.

Since metoclopramide produces a transient increase in plasma aldosterone, patients with cirrhosis or congestive heart failure may be at risk of developing fluid retention and volume overload. If these side effects occur at any time in any patients during metoclopramide therapy, the drug should be discontinued.

Adverse reactions, especially those involving the nervous system, may occur after stopping the use of METOZOLV ODT.

In clinical studies, the most frequently reported adverse events (≥2% occurrence) were headache, nausea, fatigue, somnolence, and vomiting.

Complete Prescribing Information for METOZOLV ODT, including BOXED WARNING pdf

Important Safety Information about OSMOPREP

WARNINGS

There have been rare, but serious reports of acute phosphate nephropathy in patients who received oral sodium phosphate products for colon cleansing prior to colonoscopy. Some cases have resulted in permanent impairment of renal function and some patients required long–term dialysis. While some cases have occurred in patients without identifiable risk factors, patients at increased risk of acute phosphate nephropathy may include those with increased age, hypovolemia, increased bowel transit time (such as bowel obstruction), active colitis, or baseline kidney disease, and those using medicines that affect renal perfusion or function (such as diuretics, angiotensin converting enzyme [ACE] inhibitors, angiotensin receptor blockers [ARBs], and possibly nonsteroidal anti–inflammatory drugs [NSAIDs]).

It is important to use the dose and dosing regimen as recommended (PM/AM split dose).

OSMOPREP® (sodium phosphate monobasic monohydrate, USP, and sodium phosphate dibasic anhydrous, USP) Tablets are indicated for cleansing of the colon as a preparation for colonoscopy in adults 18 years of age or older. Considerable caution should be advised before OSMOPREP is used in patients with severe renal insufficiency, congestive heart failure, ascites, unstable angina, gastric retention, ileus, severe chronic constipation, bowel perforation, toxic megacolon, gastric bypass or stapling surgery, or hypomotility syndrome. Use with caution in patients with impaired renal function, patients with a history of seizures or at higher risk of seizure, patients with higher risk of cardiac arrhythmias, known or suspected electrolyte disturbances (such as dehydration), or people taking drugs that affect electrolyte levels. Patients with electrolyte abnormalities such as hypernatremia, hyperphosphatemia, hypokalemia, or hypocalcemia should have their electrolytes corrected before treatment with OSMOPREP.

OSMOPREP is contraindicated in patients with a known allergy or hypersensitivity to sodium phosphate salts or any of its ingredients, and in patients with biopsy–proven acute phosphate nephropathy. In clinical trials, the most commonly reported adverse reactions (reporting frequency >3%) were abdominal bloating, nausea, abdominal pain, and vomiting. It is recommended that patients receiving OSMOPREP be advised to adequately hydrate before, during, and after the use of OsmoPrep.

For complete Prescribing Information for OSMOPREP including BOXED WARNING.pdf

Important Safety Information about VISICOL

WARNINGS

There have been rare, but serious reports of acute phosphate nephropathy in patients who received oral sodium phosphate products for colon cleansing prior to colonoscopy. Some cases have resulted in permanent impairment of renal function and some patients required long-term dialysis. While some cases have occurred in patients without identifiable risk factors, patients at increased risk of acute phosphate nephropathy may include those with increased age, hypovolemia, increased bowel transit time (such as bowel obstruction), active colitis, or baseline kidney disease, and those using medicines that affect renal perfusion or function (such as diuretics, angiotensin converting enzyme [ACE] inhibitors, angiotensin receptor blockers [ARBs], and possibly nonsteroidal anti-inflammatory drugs [NSAIDs]).

It is important to use the dose and dosing regimen as recommended (PM/AM split dose).

VISICOL® (sodium phosphate monobasic monohydrate, USP, and sodium phosphate dibasic anhydrous, USP) Tablets are indicated for cleansing of the colon as a preparation for colonoscopy in adults 18 years of age or older. VISICOL is not to be used in patients with congestive heart failure, ascites, unstable angina pectoris, gastric retention, ileus or acute obstruction or pseudo-obstruction, severe chronic constipation, bowel perforation, acute colitis, toxic megacolon, or hypomotility syndrome. Use with caution in patients with impaired renal function, pre-existing electrolyte disturbances, or people taking drugs that affect electrolyte levels. VISICOL is contraindicated in patients with a known allergy or hypersensitivity to sodium phosphate salts or any of its ingredients. In clinical trials, the most commonly observed (≥1%) adverse reactions occurring with use of VISICOL were generally transient and self-limited and included nausea, vomiting, abdominal bloating, abdominal pain, dizziness and headache.

Consult with your physician to see if this product is right for you.

Complete Prescribing Information for VISICOL, including BOXED WARNING pdf

The information contained on this page is intended for US patients, healthcare professionals, and pharmacists only.

Salix Pharmaceuticals on Facebook   Salix Pharmaceuticals on Twitter